查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1980188

抗凝血劑市場規模、佔有率、成長及全球產業分析：按類型、應用和地區的洞察，2026-2034年預測

Anticoagulants Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2026-2034
出版日期: | 出版商: Fortune Business Insights Pvt. Ltd. | 英文 149 Pages | 商品交期: 請詢問到貨日

價格

抗凝血劑市場的成長要素

2025年全球抗凝血劑市場規模為414.1億美元。預計該市場將從2026年的455.1億美元成長至2034年的970.9億美元，在預測期間（2026-2034年）年複合成長率高達9.93%。北美地區在2025年佔據全球市場主導地位，市場佔有率達50.70%，主要得益於該地區心血管疾病的高發生率和強大的產品創新能力。

抗凝血劑，俗稱「血液稀釋劑」，透過抑制血栓形成，在心血管疾病（CVD）的預防和治療中發揮非常重要的作用。隨著心肌梗塞、肺動脈栓塞和深層靜脈栓塞症等心血管疾病在全球的增加，對先進抗凝血療法的需求持續成長。

市場促進因素

心血管疾病盛行率不斷上升

心血管疾病仍是全球主要死因之一。全球健康評估顯示，大多數心血管疾病相關死亡是由心肌梗塞和中風引起的。抗凝血劑在治療這些疾病中非常重要，它能預防血栓形成並減少併發症。人們對心臟健康和預防保健意識的不斷提高，正顯著推動市場成長。

新型口服抗凝血劑（NOACs）的創新

新型口服抗凝血藥物（NOACs），例如Apixaban和Rivaroxaban的問世，徹底改變了治療方法。與傳統治療方法相比，這些先進藥物具有更高的安全性和便利性。旗艦產品如艾樂妥和拜瑞妥的強勁銷售業績持續推動著整體市場收入的成長。

市場區隔分析

依疾病

市場細分將這些疾病分為肺動脈栓塞（PE）、深層靜脈栓塞症（DVT）、心房顫動（AF）、心肌梗塞和其他疾病。

預計到2026年，肺動脈栓塞（PE）領域將主導市場，佔76.34%的市場佔有率。2025年，該領域創造了315.3億美元的收入，反映出治療需求強勁。肥胖症發生率上升、癌症盛行率增加以及久坐不動的生活方式是肺栓塞發病率上升的主要促進因素。

由於診斷率的提高和長期治療需求的增加，深層靜脈栓塞症（DVT）和心房顫動（AF）的細分市場也呈現穩定成長。心肌梗塞細分市場仍然十分重要，因為抗凝血劑對於二級預防非常重要。

依給藥途徑

根據給藥途徑，市場分為口服製劑和注射製劑。

預計到2026年，口服抗凝血劑將以85.58%的市場佔有率引領市場，這主要得益於患者用藥的便利性、強大的產品平臺以及新型口服抗凝血劑（NOAC）的日益普及。注射用抗凝血劑，包括Warfarin和肝素類藥物，在醫院環境中仍保持穩定的需求，但面臨口服藥物的競爭。

依通路

市場分為醫院藥局、零售藥局、網路藥局和其他藥局。

由於抗凝血藥物需要謹慎處方和監測，預計到2026年，醫院藥局將佔據46.04%的市場佔有率。零售藥房將緊隨其後，因為處方箋續藥更加便捷。同時，由於數位化的進步，預計線上藥局將呈現最高的成長率。

區域趨勢

北美洲

預計北美市場規模將在2025年達到209.8億美元，並在2026年成長至233億美元。該地區預計將在整個預測期內保持其主導地位。光是美國市場預計在2026年就將達到217.4億美元。心血管疾病的高發生率、高肥胖率以及強大的研發投入是推動該地區成長的主要因素。

歐洲

預計歐洲市場在預測期內將以7.6%的年複合成長率成長。英國市場預計到2026年將達到20.5億美元，而德國同年將達到32.5億美元。心血管疾病死亡率的上升支撐了市場需求。

亞太地區

亞太地區預計將呈現最高的成長率。日本市場規模預計2025年達到32.1億美元，2026年達到35.6億美元。中國市場預估2026年達到25.6億美元，年複合成長率高達13.40%。醫療保健支出不斷成長和健康意識的提高是成長要素。

在拉丁美洲、中東和非洲地區，由於醫療基礎設施的改善和疾病流行率的上升，預計將穩定成長。

目錄

第1章 引言

第2章 執行摘要

第3章 市場動態

  • 市場促進因素
  • 市場限制因素
  • 市場機會

第4章 主要考察

  • 主要心血管疾病盛行率：依主要國家分類
  • 新型口服抗凝血劑（NOACs）概述
  • 管道分析
  • 產業主要趨勢：併購等。
  • 新產品發布
  • 主要國家的監管狀況
  • 兌換狀態：依主要國家分類

第5章 2021-2034年全球抗凝血劑市場分析、洞察與預測

  • 主要發現與總結
  • 市場分析、洞察與預測：依適應症
    • 肺動脈栓塞（PE）
    • 深層靜脈栓塞症（DVT）
    • 心房顫動
    • 心肌梗塞
    • 其他
  • 市場分析、洞察與預測：依給藥途徑
    • 口服
    • 注射藥物
  • 市場分析、洞察與預測：依通路分類
    • 醫院和藥房
    • 零售藥房
    • 網路藥房
    • 其他
  • 市場分析、洞察與預測：依國家/地區分類
    • 北美洲
    • 歐洲
    • 亞太地區
    • 拉丁美洲
    • 中東和非洲

第6章 北美抗凝血劑市場分析、洞察與預測（2021-2034年）

  • 國家
    • 美國
    • 加拿大

第7章 歐洲抗凝血劑市場分析、洞察與預測（2021-2034年）

  • 國家
    • 英國
    • 德國
    • 法國
    • 西班牙
    • 義大利
    • 斯堪地那維亞
    • 其他歐洲國家

第8章 亞太地區抗凝血劑市場分析、洞察與預測（2021-2034年）

  • 國家
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 東南亞
    • 其他亞太國家

第9章 拉丁美洲抗凝血劑市場分析、洞察與預測（2021-2034年）

  • 國家
    • 巴西
    • 墨西哥
    • 其他拉丁美洲國家

第10章 中東和非洲抗凝血劑市場分析、洞察與預測（2021-2034年）

  • 國家
    • 海灣合作理事會國家
    • 南非
    • 其他中東和非洲國家

第11章 競爭分析

  • 主要行業趨勢
  • 全球市場佔有率分析（2025年）
  • 競爭儀錶板
  • 主要企業比較分析
    • Bristol-Myers Squibb Company
    • Pfizer Inc.
    • Bayer AG
    • Janssen Pharmaceuticals, Inc.
    • Eisai Co., Ltd.
    • 其他主要企業

第12章 戰略建議

Product Code: FBI101807

Growth Factors of anticoagulants Market

The global anticoagulants market size was valued at USD 41.41 billion in 2025. The market is projected to grow from USD 45.51 billion in 2026 to USD 97.09 billion by 2034, exhibiting a strong CAGR of 9.93% during the forecast period (2026-2034). North America dominated the global market with a 50.70% share in 2025, driven by the high prevalence of cardiovascular diseases and strong product innovation.

Anticoagulants, commonly known as blood thinners, play a critical role in preventing and treating cardiovascular diseases (CVDs) by reducing the formation of blood clots. With cardiovascular disorders such as heart attacks, strokes, pulmonary embolism, and deep vein thrombosis rising globally, demand for advanced anticoagulant therapies continues to grow.

Market Drivers

Rising Prevalence of Cardiovascular Diseases

Cardiovascular diseases remain one of the leading causes of mortality worldwide. According to global health estimates, a large percentage of deaths related to CVD are caused by heart attacks and strokes. Anticoagulants are essential in managing these conditions by preventing clot formation and reducing complications. Increasing awareness about heart health and preventive treatment significantly supports market expansion.

Innovation in Novel Oral Anticoagulants (NOACs)

The introduction of novel oral anticoagulants (NOACs), such as apixaban and rivaroxaban, has transformed treatment approaches. These advanced drugs offer improved safety profiles and convenience compared to traditional therapies. Strong sales performance of leading products like Eliquis and Xarelto continues to fuel overall market revenue growth.

Market Segmentation Analysis

By Disease Indication

The market is segmented into pulmonary embolism (PE), deep vein thrombosis (DVT), atrial fibrillation (AF), heart attacks, and others.

The pulmonary embolism (PE) segment is expected to dominate, holding a 76.34% share in 2026. In 2025, this segment generated USD 31.53 billion in revenue, reflecting high treatment demand. Rising obesity, cancer prevalence, and sedentary lifestyles are key contributors to PE incidence.

The DVT and atrial fibrillation segments also show strong growth due to increasing diagnosis rates and long-term therapy requirements. The heart attack segment remains significant, as anticoagulants are essential in secondary prevention.

By Route of Administration

Based on administration route, the market is divided into oral and injectable.

The oral segment is projected to lead with an 85.58% share in 2026, owing to patient convenience, strong product pipeline, and higher adoption of NOACs. Injectable anticoagulants, including warfarin and heparin-based drugs, maintain steady demand in hospital settings but face competition from oral alternatives.

By Distribution Channel

The market is categorized into hospital pharmacies, retail pharmacies, online pharmacies, and others.

The hospital pharmacies segment is expected to hold a 46.04% share in 2026, as anticoagulants require careful prescription and monitoring. Retail pharmacies follow closely due to refill convenience, while online pharmacies are projected to witness the fastest growth rate due to increasing digital adoption.

Regional Insights

North America

North America accounted for USD 20.98 billion in 2025 and grew to USD 23.3 billion in 2026. The region is expected to maintain dominance throughout the forecast period. The U.S. market alone was valued at USD 21.74 billion in 2026. High cardiovascular disease prevalence, obesity rates, and strong R&D initiatives drive regional growth.

Europe

Europe is anticipated to grow at a CAGR of 7.6% during the forecast period. The UK market reached USD 2.05 billion in 2026, while Germany accounted for USD 3.25 billion in 2026. Rising mortality from cardiovascular disorders supports market demand.

Asia Pacific

Asia Pacific is expected to witness the highest growth rate. Japan's market reached USD 3.21 billion in 2025 and USD 3.56 billion in 2026. China recorded USD 2.56 billion in 2026 and is projected to grow at a strong CAGR of 13.40%. Increasing healthcare expenditure and awareness are major growth factors.

Latin America and the Middle East & Africa are projected to experience steady growth due to improving healthcare infrastructure and rising disease prevalence.

Competitive Landscape

Leading players in the anticoagulants market include Bristol-Myers Squibb Company, Pfizer Inc., Bayer AG, Janssen Pharmaceuticals, Inc., and Eisai Co., Ltd. These companies dominate through strong product portfolios, strategic acquisitions, and continuous R&D investments. However, increasing generic competition may moderate pricing power in certain regions.

Conclusion

The global anticoagulants market demonstrates strong and sustained growth, rising from USD 41.41 billion in 2025 to a projected USD 97.09 billion by 2034, supported by a CAGR of 9.93%. Increasing cardiovascular disease prevalence, growing awareness, and innovation in novel oral anticoagulants are key growth drivers. While North America leads in revenue share, Asia Pacific is emerging as the fastest-growing region. Continuous R&D, strategic partnerships, and expansion into developing markets will be critical for companies aiming to strengthen their competitive position through 2034.

Segmentation By Disease Indication

  • Pulmonary Embolism (PE)
  • Deep Vein Thrombosis (DVT)
  • Atrial Fibrillation
  • Heart Attacks
  • Others

By Route of Administration

  • Oral
  • Injectable

By Distribution Channel

  • Hospitals Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • Others

By Geography

  • North America (U.S. and Canada)
  • Europe (U.K., Germany, France, Italy, Spain, Scandinavia, and Rest of Europe)
  • Asia Pacific (Japan, China, India, Australia, Southeast Asia, and Rest of Asia Pacific)
  • Latin America (Brazil, Mexico, and Rest of Latin America)
  • Middle East & Africa (South Africa, GCC and Rest of Middle East & Africa)

Table of Content

1. Introduction

  • 1.1. Research Scope
  • 1.2. Market Segmentation
  • 1.3. Research Methodology
  • 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities

4. Key Insights

  • 4.1. Prevalence of Major Cardiovascular Diseases by Key Countries
  • 4.2. Overview of Novel Oral Anticoagulants (NOACs)
  • 4.3. Pipeline Analysis
  • 4.4. Key Industry Developments Such as Mergers & Acquisitions
  • 4.5. New Product Launches
  • 4.6. Regulatory Scenario in Key Countries
  • 4.7. Reimbursement Scenario by Key Countries

5. Global Anticoagulants Market Analysis, Insights and Forecast, 2021-2034

  • 5.1. Key Findings / Summary
  • 5.2. Market Analysis, Insights and Forecast - By Disease Indication
    • 5.2.1. Pulmonary Embolism (PE)
    • 5.2.2. Deep Vein Thrombosis (DVT)
    • 5.2.3. Atrial Fibrillation
    • 5.2.4. Heart Attacks
    • 5.2.5. Others
  • 5.3. Market Analysis, Insights and Forecast - By Route of Administration
    • 5.3.1. Oral
    • 5.3.2. Injectable
  • 5.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 5.4.1. Hospitals Pharmacies
    • 5.4.2. Retail Pharmacies
    • 5.4.3. Online Pharmacies
    • 5.4.4. Others
  • 5.5. Market Analysis, Insights and Forecast - By Country
    • 5.5.1. North America
    • 5.5.2. Europe
    • 5.5.3. Asia pacific
    • 5.5.4. Latin America
    • 5.5.5. Middle East & Africa

6. North America Anticoagulants Market Analysis, Insights and Forecast, 2021-2034

  • 6.1. Key Findings / Summary
  • 6.2. Market Analysis - By Disease Indication
    • 6.2.1. Pulmonary Embolism (PE)
    • 6.2.2. Deep Vein Thrombosis (DVT)
    • 6.2.3. Atrial Fibrillation
    • 6.2.4. Heart Attacks
    • 6.2.5. Others
  • 6.3. Market Analysis - By Route of Administration
    • 6.3.1. Oral
    • 6.3.2. Injectable
  • 6.4. Market Analysis - By Distribution Channel
    • 6.4.1. Hospitals Pharmacies
    • 6.4.2. Retail Pharmacies
    • 6.4.3. Online Pharmacies
    • 6.4.4. Others
  • 6.5. Market Analysis - By Country
    • 6.5.1. U.S.
    • 6.5.2. Canada

7. Europe Anticoagulants Market Analysis, Insights and Forecast, 2021-2034

  • 7.1. Key Findings / Summary
  • 7.2. Market Analysis - By Disease Indication
    • 7.2.1. Pulmonary Embolism (PE)
    • 7.2.2. Deep Vein Thrombosis (DVT)
    • 7.2.3. Atrial Fibrillation
    • 7.2.4. Heart Attacks
    • 7.2.5. Others
  • 7.3. Market Analysis - By Route of Administration
    • 7.3.1. Oral
    • 7.3.2. Injectable
  • 7.4. Market Analysis - By Distribution Channel
    • 7.4.1. Hospitals Pharmacies
    • 7.4.2. Retail Pharmacies
    • 7.4.3. Online Pharmacies
    • 7.4.4. Others
  • 7.5. Market Analysis - By Country
    • 7.5.1. U.K.
    • 7.5.2. Germany
    • 7.5.3. France
    • 7.5.4. Spain
    • 7.5.5. Italy
    • 7.5.6. Scandinavia
    • 7.5.7. Rest of Europe

8. Asia Pacific Anticoagulants Market Analysis, Insights and Forecast, 2021-2034

  • 8.1. Key Findings / Summary
  • 8.2. Market Analysis - By Disease Indication
    • 8.2.1. Pulmonary Embolism (PE)
    • 8.2.2. Deep Vein Thrombosis (DVT)
    • 8.2.3. Atrial Fibrillation
    • 8.2.4. Heart Attacks
    • 8.2.5. Others
  • 8.3. Market Analysis - By Route of Administration
    • 8.3.1. Oral
    • 8.3.2. Injectable
  • 8.4. Market Analysis - By Distribution Channel
    • 8.4.1. Hospitals Pharmacies
    • 8.4.2. Retail Pharmacies
    • 8.4.3. Online Pharmacies
    • 8.4.4. Others
  • 8.5. Market Analysis - By Country
    • 8.5.1. Japan
    • 8.5.2. China
    • 8.5.3. India
    • 8.5.4. Australia
    • 8.5.5. Southeast Asia
    • 8.5.6. Rest of Asia Pacific

9. Latin America Anticoagulants Market Analysis, Insights and Forecast, 2021-2034

  • 9.1. Key Findings / Summary
  • 9.2. Market Analysis - By Disease Indication
    • 9.2.1. Pulmonary Embolism (PE)
    • 9.2.2. Deep Vein Thrombosis (DVT)
    • 9.2.3. Atrial Fibrillation
    • 9.2.4. Heart Attacks
    • 9.2.5. Others
  • 9.3. Market Analysis - By Route of Administration
    • 9.3.1. Oral
    • 9.3.2. Injectable
  • 9.4. Market Analysis - By Distribution Channel
    • 9.4.1. Hospitals Pharmacies
    • 9.4.2. Retail Pharmacies
    • 9.4.3. Online Pharmacies
    • 9.4.4. Others
  • 9.5. Market Analysis - By Country
    • 9.5.1. Brazil
    • 9.5.2. Mexico
    • 9.5.3. Rest of Latin America

10. Middle East & Africa Anticoagulants Market Analysis, Insights and Forecast, 2021-2034

  • 10.1. Key Findings / Summary
  • 10.2. Market Analysis - By Disease Indication
    • 10.2.1. Pulmonary Embolism (PE)
    • 10.2.2. Deep Vein Thrombosis (DVT)
    • 10.2.3. Atrial Fibrillation
    • 10.2.4. Heart Attacks
    • 10.2.5. Others
  • 10.3. Market Analysis - By Route of Administration
    • 10.3.1. Oral
    • 10.3.2. Injectable
  • 10.4. Market Analysis - By Distribution Channel
    • 10.4.1. Hospitals Pharmacies
    • 10.4.2. Retail Pharmacies
    • 10.4.3. Online Pharmacies
    • 10.4.4. Others
  • 10.5. Market Analysis - By Country
    • 10.5.1. GCC Countries
    • 10.5.2. South Africa
    • 10.5.3. Rest of Middle East & Africa

11. Competitive Analysis

  • 11.1. Key Industry Developments
  • 11.2. Global Market Share Analysis (2025)
  • 11.3. Competition Dashboard
  • 11.4. Comparative Analysis - Major Players
    • 11.4.1. Bristol-Myers Squibb Company
      • 11.4.1.1. Overview,
      • 11.4.1.2. Products & services,
      • 11.4.1.3. SWOT analysis,
      • 11.4.1.4. Recent developments,
      • 11.4.1.5. strategies,
      • 11.4.1.6. financials (based on availability)
    • 11.4.2. Pfizer Inc.
      • 11.4.2.1. Overview,
      • 11.4.2.2. Products & services,
      • 11.4.2.3. SWOT analysis,
      • 11.4.2.4. Recent developments,
      • 11.4.2.5. strategies,
      • 11.4.2.6. financials (based on availability)
    • 11.4.3. Bayer AG
      • 11.4.3.1. Overview,
      • 11.4.3.2. Products & services,
      • 11.4.3.3. SWOT analysis,
      • 11.4.3.4. Recent developments,
      • 11.4.3.5. strategies,
      • 11.4.3.6. financials (based on availability)
    • 11.4.4. Janssen Pharmaceuticals, Inc.
      • 11.4.4.1. Overview,
      • 11.4.4.2. Products & services,
      • 11.4.4.3. SWOT analysis,
      • 11.4.4.4. Recent developments,
      • 11.4.4.5. strategies,
      • 11.4.4.6. financials (based on availability)
    • 11.4.5. Eisai Co., Ltd.
      • 11.4.5.1. Overview,
      • 11.4.5.2. Products & services,
      • 11.4.5.3. SWOT analysis,
      • 11.4.5.4. Recent developments,
      • 11.4.5.5. strategies,
      • 11.4.5.6. financials (based on availability)
    • 11.4.6. Other Prominent Players
      • 11.4.6.1. Overview,
      • 11.4.6.2. Products & services,
      • 11.4.6.3. SWOT analysis,
      • 11.4.6.4. Recent developments,
      • 11.4.6.5. strategies,
      • 11.4.6.6. financials (based on availability)

12. Strategic Recommendations

List of Tables

  • Table 1: Global Anticoagulants Market Revenue (US$ Mn) Forecast, by Disease Indication, 2021-2034
  • Table 2: Global Anticoagulants Market Revenue (US$ Mn) Forecast, by Route of Administration, 2021-2034
  • Table 3: Global Anticoagulants Market Revenue (US$ Mn) Forecast, by Distribution Channel, 2021-2034
  • Table 4: Global Anticoagulants Market Revenue (US$ Mn) Forecast, by Region, 2021-2034
  • Table 5: North America Anticoagulants Market Revenue (US$ Mn) Forecast, by Disease Indication, 2021-2034
  • Table 6: North America Anticoagulants Market Revenue (US$ Mn) Forecast, by Route of Administration, 2021-2034
  • Table 7: North America Anticoagulants Market Revenue (US$ Mn) Forecast, by Distribution Channel, 2021-2034
  • Table 8: North America Anticoagulants Market Revenue (US$ Mn) Forecast, By Country, 2021-2034
  • Table 9: Europe Anticoagulants Market Revenue (US$ Mn) Forecast, by Disease Indication, 2021-2034
  • Table 10: Europe Anticoagulants Market Revenue (US$ Mn) Forecast, by Route of Administration, 2021-2034
  • Table 11: Europe Anticoagulants Market Revenue (US$ Mn) Forecast, by Distribution Channel, 2021-2034
  • Table 12: Europe Anticoagulants Market Revenue (US$ Mn) Forecast, By Country/ Sub-region, 2021-2034
  • Table 13: Asia Pacific Anticoagulants Market Revenue (US$ Mn) Forecast, by Disease Indication, 2021-2034
  • Table 14: Asia Pacific Anticoagulants Market Revenue (US$ Mn) Forecast, by Route of Administration, 2021-2034
  • Table 15: Asia Pacific Anticoagulants Market Revenue (US$ Mn) Forecast, by Distribution Channel, 2021-2034
  • Table 16: Asia Pacific Anticoagulants Market Revenue (US$ Mn) Forecast, By Country/ Sub-region, 2021-2034
  • Table 17: Latin America Anticoagulants Market Revenue (US$ Mn) Forecast, by Disease Indication, 2021-2034
  • Table 18: Latin America Anticoagulants Market Revenue (US$ Mn) Forecast, by Route of Administration, 2021-2034
  • Table 19: Latin America Anticoagulants Market Revenue (US$ Mn) Forecast, by Distribution Channel, 2021-2034
  • Table 20: Latin America Anticoagulants Market Revenue (US$ Mn) Forecast, By Country/ Sub-region, 2021-2034
  • Table 21: Middle East & Africa Anticoagulants Market Revenue (US$ Mn) Forecast, by Disease Indication, 2021-2034
  • Table 22: Middle East & Africa Anticoagulants Market Revenue (US$ Mn) Forecast, by Route of Administration, 2021-2034
  • Table 23: Middle East & Africa Anticoagulants Market Revenue (US$ Mn) Forecast, by Distribution Channel, 2021-2034
  • Table 24: Middle East & Africa Anticoagulants Market Revenue (US$ Mn) Forecast, By Country/ Sub-region, 2021-2034

List of Figures

  • Figure 1: Global Anticoagulants Market Revenue Breakdown (US$ Mn, %) by Region, 2025-2034
  • Figure 2: Global Anticoagulants Market Value Share (%), by Disease Indication, 2025-2034
  • Figure 3: Global Anticoagulants Market Forecast (US$ Mn), by Pulmonary Embolism (PE), 2021-2034
  • Figure 4: Global Anticoagulants Market Forecast (US$ Mn), by Deep Vein Thrombosis (DVT), 2021-2034
  • Figure 5: Global Anticoagulants Market Forecast (US$ Mn), by Atrial Fibrillation, 2021-2034
  • Figure 6: Global Anticoagulants Market Forecast (US$ Mn), by Heart Attacks, 2021-2034
  • Figure 7: Global Anticoagulants Market Forecast (US$ Mn), by Others, 2021-2034
  • Figure 8: Global Anticoagulants Market Value Share (%), by Route of Administration, 2025-2034
  • Figure 9: Global Anticoagulants Market Forecast (US$ Mn), by Oral, 2021-2034
  • Figure 10: Global Anticoagulants Market Forecast (US$ Mn), by Injectable, 2021-2034
  • Figure 11: Global Anticoagulants Market Value Share (%), by Distribution Channel, 2025-2034
  • Figure 12: Global Anticoagulants Market Forecast (US$ Mn), by Hospitals Pharmacies, 2021-2034
  • Figure 13: Global Anticoagulants Market Forecast (US$ Mn), by Retail Pharmacies, 2021-2034
  • Figure 14: Global Anticoagulants Market Forecast (US$ Mn), by Online Pharmacies, 2021-2034
  • Figure 15: Global Anticoagulants Market Forecast (US$ Mn), by Others, 2021-2034
  • Figure 16: Global Anticoagulants Market Value (US$ Mn), by Region, 2025-2034
  • Figure 17: North America Anticoagulants Market Value (US$ Mn), by Disease Indication, 2025-2034
  • Figure 18: North America Anticoagulants Market Value Share (%), by Disease Indication, 2025
  • Figure 19: North America Anticoagulants Market Value (US$ Mn), by Route of Administration, 2025-2034
  • Figure 20: North America Anticoagulants Market Value Share (%), by Route of Administration, 2025
  • Figure 21: North America Anticoagulants Market Value (US$ Mn), by Distribution Channel, 2025-2034
  • Figure 22: North America Anticoagulants Market Value Share (%), by Distribution Channel, 2025
  • Figure 23: North America Anticoagulants Market Value (US$ Mn), By Country, 2025-2034
  • Figure 24: North America Anticoagulants Market Value Share (%), By Country, 2025
  • Figure 25: Europe Anticoagulants Market Value (US$ Mn), by Disease Indication, 2025-2034
  • Figure 26: Europe Anticoagulants Market Value Share (%), by Disease Indication, 2025
  • Figure 27: Europe Anticoagulants Market Value (US$ Mn), by Route of Administration, 2025-2034
  • Figure 28: Europe Anticoagulants Market Value Share (%), by Route of Administration, 2025
  • Figure 29: Europe Anticoagulants Market Value (US$ Mn), by Distribution Channel, 2025-2034
  • Figure 30: Europe Anticoagulants Market Value Share (%), by Distribution Channel, 2025
  • Figure 31: Europe Anticoagulants Market Value (US$ Mn), By Country/ Sub-region, 2025-2034
  • Figure 32: Europe Anticoagulants Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 33: Asia Pacific Anticoagulants Market Value (US$ Mn), by Disease Indication, 2025-2034
  • Figure 34: Asia Pacific Anticoagulants Market Value Share (%), by Disease Indication, 2025
  • Figure 35: Asia Pacific Anticoagulants Market Value (US$ Mn), by Route of Administration, 2025-2034
  • Figure 36: Asia Pacific Anticoagulants Market Value Share (%), by Route of Administration, 2025
  • Figure 37: Asia Pacific Anticoagulants Market Value (US$ Mn), by Distribution Channel, 2025-2034
  • Figure 38: Asia Pacific Anticoagulants Market Value Share (%), by Distribution Channel, 2025
  • Figure 39: Asia Pacific Anticoagulants Market Value (US$ Mn), By Country/ Sub-region, 2025-2034
  • Figure 40: Asia Pacific Anticoagulants Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 41: Latin America Anticoagulants Market Value (US$ Mn), by Disease Indication, 2025-2034
  • Figure 42: Latin America Anticoagulants Market Value Share (%), by Disease Indication, 2025
  • Figure 43: Latin America Anticoagulants Market Value (US$ Mn), by Route of Administration, 2025-2034
  • Figure 44: Latin America Anticoagulants Market Value Share (%), by Route of Administration, 2025
  • Figure 45: Latin America Anticoagulants Market Value (US$ Mn), by Distribution Channel, 2025-2034
  • Figure 46: Latin America Anticoagulants Market Value Share (%), by Distribution Channel, 2025
  • Figure 47: Latin America Anticoagulants Market Value (US$ Mn), By Country/ Sub-region, 2025-2034
  • Figure 48: Latin America Anticoagulants Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 49: Middle East & Africa Anticoagulants Market Value (US$ Mn), by Disease Indication, 2025-2034
  • Figure 50: Middle East & Africa Anticoagulants Market Value Share (%), by Disease Indication, 2025
  • Figure 51: Middle East & Africa Anticoagulants Market Value (US$ Mn), by Route of Administration, 2025-2034
  • Figure 52: Middle East & Africa Anticoagulants Market Value Share (%), by Route of Administration, 2025
  • Figure 53: Middle East & Africa Anticoagulants Market Value (US$ Mn), by Distribution Channel, 2025-2034
  • Figure 54: Middle East & Africa Anticoagulants Market Value Share (%), by Distribution Channel, 2025
  • Figure 55: Middle East & Africa Anticoagulants Market Value (US$ Mn), By Country/ Sub-region, 2025-2034
  • Figure 56: Middle East & Africa Anticoagulants Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 57: Global Anticoagulants Market Share (%), By Company, 2025